Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Keldsen

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Ugeskrift for Laeger|August 12, 1991
[Intracavitary irradiation of esophageal cancer]N Keldsen, J Bentzen, J B Knudsen, et al.
Ugeskrift for Laeger|January 2, 1995
[Attitudes to autopsy among critically ill patients and the general population]N Keldsen, H Nødskov, H Nielsen, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1996
Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysisN Keldsen, W Michalski, S M Bentzen, et al.
Gynecologic Oncology|June 13, 1998
Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study. The Danish Ovarian Cancer Study GroupN Keldsen, E L Madsen, H Havsteen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2009
A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancerC Qvortrup, B V Jensen, T Fokstuen, et al.
European Journal of Haematology|August 1, 1993
Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG)N Keldsen, O W Bjerrum, I M Dahl, et al.
British Journal of Haematology|January 1, 1991
Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG)P Gimsing, O W Bjerrum, E Brandt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2008
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancerB Glimelius, H Sørbye, L Balteskard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancerC Frederiksen, C Qvortrup, I J Christensen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2013
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT TrialA Johnsson, H Hagman, J-E Frödin, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Ugeskrift for Laeger|August 12, 1991
[Intracavitary irradiation of esophageal cancer]N Keldsen, J Bentzen, J B Knudsen, et al.
Ugeskrift for Laeger|January 2, 1995
[Attitudes to autopsy among critically ill patients and the general population]N Keldsen, H Nødskov, H Nielsen, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1996
Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysisN Keldsen, W Michalski, S M Bentzen, et al.
Gynecologic Oncology|June 13, 1998
Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study. The Danish Ovarian Cancer Study GroupN Keldsen, E L Madsen, H Havsteen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2009
A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancerC Qvortrup, B V Jensen, T Fokstuen, et al.
European Journal of Haematology|August 1, 1993
Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG)N Keldsen, O W Bjerrum, I M Dahl, et al.
British Journal of Haematology|January 1, 1991
Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG)P Gimsing, O W Bjerrum, E Brandt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2008
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancerB Glimelius, H Sørbye, L Balteskard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancerC Frederiksen, C Qvortrup, I J Christensen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2013
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT TrialA Johnsson, H Hagman, J-E Frödin, et al.
Pageof 3